Research Award (Denali Therapeutics), 2022-2025.
Project Description:
A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II. Paul Hillman, MD (Site PI).
Keyword(s):
Clinical Care, Developmental Disabilities
Area of Emphasis
Health-Related Activities
Target Audience:
Students/Trainees (long or intermediate trainees), Professionals and Para-Professionals
Unserved or Under-served Populations:
None
Primary Target Audience Geographic Descriptor:
Single-County
COVID-19 Related Data:
N/A